FDA moves toward easing restrictions on certain peptides BioPharma Dive In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and